Trospium blocks the muscarinic acetylcholine receptor, so Xanomeline cannot act there — the effect of Xanomeline is reduced or lost.
Xanomeline is an agonist at the muscarinic acetylcholine receptor: it binds and switches the receptor on. Trospium is an antagonist at the same site and switches nothing on. With both present they compete for the same pocket, and whichever is there in greater effective concentration decides what the receptor does.
Given together they work against whatever each was started for. If both are genuinely needed, expect less of Xanomeline’s effect than its dose would suggest.
This is a pharmacodynamic interaction. Neither drug changes the other’s concentration, so a level, an AUC estimate or a genotype looks entirely normal while the clinical effect is blunted.
The direction can be the useful one. The same opposition is what makes a reversal agent, an antidote or a planned antagonist work.



The ring marks the peg each drug wears for this receptor — the same cross-illumination Interact! draws when the two are put side by side.

